See every side of every news story
Get Started
SubscribeLogin
Israel-Hamas Conflict
Donald Trump
Artificial Intelligence
Social Media
Natural Disasters
US Politics
Republican Party
Education
Democratic Party
Floods
Crime
Infrastructure
US Crime
ILCN.org (ILCN/WCLC) image

News from ILCN.org (ILCN/WCLC)

If you want to know if ILCN.org (ILCN/WCLC) is credible or reliable, look no further. We rank ILCN.org (ILCN/WCLC) as Unknown factuality. Find out more about our methodology here.

Information about ILCN.org (ILCN/WCLC)

Where is ILCN.org (ILCN/WCLC) located?ILCN.org (ILCN/WCLC)'s Website

Media Bias Ratings

Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.

Factuality

Learn more about  Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about  Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top ILCN.org (ILCN/WCLC) News

SACHI Trial Results: Savolitinib-Osimertinib Combo Improves PFS in MET-Amplified EGFR-Mutated NSCLC - ILCN.org (ILCN/WCLC)
Maryland · Maryland

SACHI Trial Results: Savolitinib-Osimertinib Combo Improves PFS in MET-Amplified EGFR-Mutated NSCLC - ILCN.org (ILCN/WCLC)

MET amplification is a key resistance mechanism in more than 20% of pretreated EGFR-mutant non-small cell lung cancer (NSCLC) cases. It’s also tied to early disease progression and poor prognosis. Shun Lu, MD, PhD Biomarker-guided treatment options after progression on EGFR-tyrosine kinase inhibitor (TKI) therapy remain limited. Until recently, no randomized study has addressed the role of targeted therapies for MET-amplification in this clinic…Read Article
IMpower010 Trial Update Highlights Long-Term Benefits of Adjuvant Atezolizumab in Resected NSCLC - ILCN.org (ILCN/WCLC)
Maryland · Maryland

IMpower010 Trial Update Highlights Long-Term Benefits of Adjuvant Atezolizumab in Resected NSCLC - ILCN.org (ILCN/WCLC)

The IMpower010 trial has previously demonstrated improvements in disease-free survival (DFS) compared with best supportive care (BSC) for patients with resected stage II-IIIA non-small cell lung cancer (NSCLC). While the trial did not achieve the statistical significance boundary in the intent-to-treat (ITT) population during its first interim analysis, recently published 5-year data as well as an exploratory, retrospective analysis of genomic p…Read Article
Bispecific T-cell Engagers: Understanding the Evolving and Innovative Approaches to Outpatient Side Effect Management - ILCN.org (ILCN/WCLC)
Maryland · Maryland

Bispecific T-cell Engagers: Understanding the Evolving and Innovative Approaches to Outpatient Side Effect Management - ILCN.org (ILCN/WCLC)

Dr. Melissa L. Johnson, director of lung cancer research at Sarah Cannon Research Institute, took the podium in an education session on bispecific T-cell engagers at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting this past June. Dr. Johnson discussed some of the obstacles that community practices face in implementing these novel agents, especially regarding the potentially serious associated side effects of cytokine release…Read Article

IASLC Committee Spotlight: Multidisciplinary Clinical Science Committee - ILCN.org (ILCN/WCLC)

Established within the past two years, the IASLC Multidisciplinary Clinical Science Committee is one of the IASLC’s newer committees. However, it has already launched several key projects. Thomas “Tom” E. Stinchcombe, the Committee Chair, provided an overview of the committee’s projects and its overarching mission. Thomas E. Stinchcombe, MD ILCN: For readers who may be unfamiliar, can you briefly share the mission and goals of the Multidiscipli…Australia · AustraliaRead Article

A Paradigm Shift: Final 5-Year Overall Survival Results from CheckMate 816 in Resectable NSCLC - ILCN.org (ILCN/WCLC)

The CheckMate 816 trial, which evaluated neoadjuvant nivolumab in combination with chemotherapy, demonstrated a significant survival advantage versus chemotherapy alone in patients with resectable non-small cell lung cancer (NSCLC). Patrick Forde, MD Additionally, data confirmed a durable event-free survival (EFS) benefit. Patrick M. Forde, MD, PhD, Trinity St. James’s Cancer Institute, Trinity College Dublin, presented the latest and final ove…Maryland · MarylandRead Article

Patient Perspective: Copay Accumulators Create Yet Another Cost Burden Faced by US Patients in Treatment with Targeted Therapies - ILCN.org (ILCN/WCLC)

Adding to the Kafkaesque financial toxicities that can accompany long-term treatment—I’m required by the internationally recognized rules of patient engagement to invoke an allusion to Kafka—is an insurance scheme that is short on transparency, shifts the burden of cost to the patient, and which has become a widespread practice in the United States: copay accumulators and maximizers. Annabelle Gurwitch As Monica Bryant, COO of Triage Cancer put…United States · United StatesRead Article

Research to Watch: FDA Grants ZL-1310 Fast Track Designation for Extensive-Stage SCLC - ILCN.org (ILCN/WCLC)

The US Food and Drug Administration (FDA) has granted Fast Track Designation to ZL-1310 for the treatment of extensive-stage small cell lung cancer (ES-SCLC). This decision underscores the ongoing need to develop new therapies for patients with small cell lung cancer (SCLC) and marks an important step forward in clinical progress. The designation is based on updated results from an ongoing phase 1a/1b trial, which were presented at the 2025 Amer…Research · United StatesRead Article

MHRA Approves Serplulimab for Extensive-Stage SCLC

67% Center coverage: 3 sources
The MHRA has approved serplulimab, the UK’s first anti-PD-1 antibody for extensive-stage small cell lung cancer, improving survival options for adults.FDA · United StatesSee the Story

Rethinking Radiation: Adopting Hypofractionated Radiation Therapy - ILCN.org (ILCN/WCLC)

Puneeth Iyengar, MD, PhD, and Edward Christopher Dee, MD, recently discussed the environmental costs of cancer treatment in an interview with ILCN. In part two of our series, Dr. Iyengar, a radiation oncologist at Memorial Sloan Kettering Cancer Center (MSKCC), New York, and Dr. Dee, a third-year resident at MSKCC, explore the benefits and challenges of adopting hypofractionated radiation schedules. Puneeth Iyengar, MD, PhD ILCN: What is hypofr…Maryland · MarylandRead Article

Global Insights into Smoking Cessation in Lung Cancer Screening - ILCN.org (ILCN/WCLC)

Rachael Murray, PhD, MS, BSc Smoking cessation interventions are a critical component of lung cancer screening (LCS) programs, as they have been shown to reduce smoking-related risks and improve screening outcomes. Evidence increasingly supports the inclusion of high-intensity and opt-out smoking cessation services at the point of screening as having the greatest impact. Despite this, the implementation of cessation support within LCS programs v…United States · United StatesRead Article

Lurbinectedin Maintenance Combo Earns FDA Priority Review in ES-SCLC

Coverage: 2 sources
The FDA has set a Prescription Drug User Fee Act date of October 7, 2025, for its decision on approving the lurbinectedin combination in this SCLC population.Medical · United StatesSee the Story

Breaking News Topics Related to ILCN.org (ILCN/WCLC)

Maryland icon

Maryland

Texas, United States icon

Texas, United States

Research icon

Research

FDA icon

FDA

United States icon

United States

News
For You
SearchBlindspotLocal